Stocks · News reference
INmune Bio Submits Two Regulatory Packages To EMA For Ebstrocel: Application For Orphan Drug Designation And Scientific Advice Package To Streamline Upcoming MAA In Europe
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEBFilings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 26, 2026, 11:15 AM
- Checked
- Aug 26, 2026, 11:15 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Inmune Bio, Inc. (INMB)
Filed: 2026-07-31 AccNo: 0001213900-26-083961 Size: 231 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarINmune Bio Reaches Manufacturing Milestone with First Commercial-Ready CORDStrom Umbilical Cord Tissue Processed At CGT Catapult In Partnership With Anthony Nolan Cord Blood Bank
Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.Company Expresses Support for MHRA Draft Rare Disease Therapies
Read original at benzinga